An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy

  • End date
    Sep 20, 2022
  • participants needed
  • sponsor
    Jazz Pharmaceuticals
Updated on 20 August 2021
Associate Director Clinical Trial Disclosure
Primary Contact
Clinical Research of Rock Hill (3.3 mi away) Contact
+19 other location


The rationale for the interventional, open-label, single-arm design of JZP258-401 is to evaluate the clinical experience in participants with narcolepsy transitioning treatment from Xyrem to XYWAV.

Condition Narcolepsy
Treatment JZP-258
Clinical Study IdentifierNCT04794491
SponsorJazz Pharmaceuticals
Last Modified on20 August 2021


Yes No Not Sure

Inclusion Criteria

Participant must be 18 to 80 years of age (inclusive), at the time of signing the informed consent. Type of Participant and Disease Characteristics
Participants who have a primary diagnosis of Type 1 or Type 2 narcolepsy that meets ICSD-3 criteria or DSM-5 criteria (Ruoff and Rye 2016), and are being currently treated with Xyrem, with or without additional anticataplectics or stimulants
Participants who have been taking Xyrem (with or without additional anticataplectics or stimulants eg, TCA, SNRI, SSRI, atomoxetine) in a stable dose and regimen for at least two months prior to screening, with evidence of clinical improvement on their current regimen, per the investigator's judgement. Only Xyrem will be substituted with XYWAV, with dose and regimen of any concomitant anticataplectics or stimulants remaining unchanged throughout the study
Sex and Contraceptive/Barrier Requirements
\. Participant is male or female
A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies
Is a woman of non-childbearing potential (WONCBP) as defined in Appendix 3 OR
Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of < 1% per year), preferably with low user dependency, as described in Appendix 3, during the study Intervention period and for at least 7 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (eg, noncompliance, recently initiated) in relationship to the first dose of study intervention
A WOCBP must have a negative highly sensitive pregnancy test (serum) during screening
The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy
Informed Consent
\. Capable of giving signed informed consent, which includes compliance with
the requirements and restrictions listed in the informed consent form (ICF)
and in this protocol

Exclusion Criteria

Medical Conditions
Have a diagnosis of narcolepsy, secondary to another medical condition (eg, central nervous system injury or lesion)
Are currently prescribed a Xyrem regimen exceeding a dose of 9 grams nightly, or any single dose in excess of 6 grams
Have been diagnosed with restless leg syndrome (RLS) requiring treatment other than iron supplements
Exhibit succinic semi-aldehyde dehydrogenase deficiency (SSADH)
Have uncontrolled hypothyroidism
Have a history of seizures, excluding early childhood non-pathological febrile seizures
Have a history of head trauma associated with loss of consciousness in the past 5 years, or if the event occurred more than 5 years prior to screening and the participant experiences sequelae due to the event
Show evidence of untreated or inadequately treated sleep-disordered breathing
Presence of clinically significant and untreated obstructive or central sleep apnea (as determined by the investigator or documented previously); or one of the
Apnea index (AI) >10 if on Obstructive Sleep Apnea (OSA) treatment or untreated, or
Clinically significant hypoventilation, or
Noncompliance with primary OSA therapy Note: "Non-compliance" is defined as positive airway pressure use of <4 hours per night on <70% of nights (<5 of 7 nights/week) per historical report (with investigator concurrence) of use of an oral appliance on <70% of nights (5 of 7 nights/week), or receipt of an effective surgical intervention for OSA symptoms
Experience parasomnias (eg, sleep walking, REM Sleep Behavior Disorder, etc.) considered by the investigator to negatively impact the conduct of the study. Parasomnia events associated with physical injury to the participant (or others) shall be discussed with the sponsor Medical Monitor
Meet criteria for current major depression based on clinical interview
Have any clinically relevant medical, behavioral, or psychiatric disorder (other than narcolepsy) that is associated with excessive sleepiness
Have a history or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria
Have a history or presence of any unstable or clinically significant medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or history or presence of another neurological disorder or surgical history that might affect the participant's safety and/or interfere with the conduct of the study, in the opinion of the investigator
Display relevant suicidality as indicated by Columbia Suicide Severity Rating Scale (C-SSRS) evaluation at screening
Display moderate to severe depression as indicated by the Participant Health Questionnaire - 9 (PHQ-9) at screening
Are a female participant who is pregnant or breastfeeding
Prior/Concomitant Therapy
\. Have undergone treatment with any prohibited central nervous system (CNS)
agents, including but not limited to benzodiazepines, non-benzodiazepine
anxiolytics/ hypnotics/sedatives, neuroleptics, opioids, barbiturates
phenytoin, ethosuximide, or MCT inhibitors, eg, diclofenac, valproate
ibuprofen, within 2 weeks prior to enrollment. Discontinuation for the purpose
of study enrollment is permitted only if considered safe by the investigator
and approved by the Medical Monitors
Prior/Concurrent Clinical Study Experience
\. Received any other investigational drug within 30 days or five half-lives
(whichever is longer) prior to screening, or plan to use an investigational
drug (other than the study intervention) during the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note